Clinical Trial Update: Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC [Phase 3]

View source ↗

Summary

A randomized Phase III trial comparing FOLFIRI plus bevacizumab versus XELIRI plus bevacizumab as first-line treatment for colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (Avastin) (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• XELIRI

Snippet

Sponsor: Hellenic Oncology Research Group | Conditions: Colorectal Cancer | Phase 3 | Status: COMPLETED